<?xml version="1.0" encoding="UTF-8"?>
<p id="Par51">Currently available TIV vaccines are not approved for children under 6 months of age because they may not have a fully mature immune system [
 <xref ref-type="bibr" rid="CR88">88</xref>]. Trivalent vaccines, specifically in use, are antigenically homologous to a novel influenza strain. Therefore, this does not require a separate pandemic influenza vaccine. The importance of LAIV marketing and use exists in terms of faster production, a good safety profile, less resource-intensive and cost-effective compared to the inactivated influenza vaccine. In India, after seeing evidence of immunogenicity, quality control and safety in the clinical investigation, pandemic influenza A vaccines have been licensed by the Drug Controller General India (DCGI) and have been available since September 2010 [
 <xref ref-type="bibr" rid="CR90">90</xref>]. In the preliminary phase, the Government of India offered &gt; 2.5 million doses of pandemic influenza to immunize high-risk groups, social and medical staff and emergency unit personnel across India, of whom Karnataka alone used ~ 1 million doses [
 <xref ref-type="bibr" rid="CR91">91</xref>].
</p>
